We chose two NSCLC cell lines originating from the C57BL/6 background, Lewis lung carcinoma (LLC) and a KRAS G12D mutant cell line with concurrent loss of TP53 and STK11/LKB1 (KPL) [8], genetic alterations commonly co-occurring with KRAS mutations in human NSCLC [21]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.